

Pilot Evaluation of IDEXX Cancer Dx™ Testing for Monitoring CHOP Treatment Response in Canine Lymphoma

Amanda Nascimento¹, Sarah Peterson¹, Dana Connell¹, Zachary Helm¹, Rachel Venable²


1. IDEXX Laboratories, Inc.
2. Pet Cancer Care Consulting

Introduction

- IDEXX Cancer Dx testing is a minimally invasive, blood-based diagnostic test with 79% sensitivity and 99% specificity for detecting lymphoma in treatment-naïve dogs.
- This pilot study explored the potential of Cancer Dx testing for monitoring treatment response during CHOP chemotherapy.

Methods

- Prospective enrollment of dogs with naïve lymphoma and undergoing a 25-week CHOP protocol.
- Clinical response defined by WHO criteria
- Cytology or histology reviewed by a boarded pathologist along with phenotype or genotype determination by flow cytometry or PARR*, respectively and response to CHOP were required for inclusion in analysis.



Results

Table 1. Longitudinal Cancer Dx Testing Results and Clinical Responses in 10 Dogs.

Dog #	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17	V18	V19	V20	V21	V22	V23	V24				
1	+	PR	PR	PR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	PD	SD	PD	PR	SD	PD	PR	
2	+	CR	PD	CR	CR	CR	CR	CR	PD	SW																		
3	+	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR															
4	+	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR															
5	+	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR															
6	+	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR															
7	+	PR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR														
8	+	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR	CR															
9	+	CR	PD	PD	PR																							
10	+	PR	SD	SD	CR	CR																						

 Cancer Dx test positive	CR= Complete remission	Changes in clinical remission status are bolded.
 Cancer Dx test negative	PR= Partial remission	
	SD= Stable disease	
	PD= Progressive disease SW= Study Withdrawal	

Remission (CR) Outcomes:

- **10/10** dogs had positive Cancer Dx test results and all achieved CR, all became negative during treatment according to Cancer Dx test results.
- **3/10** dogs progressed during the protocol; **2/3** dogs had positive Cancer Dx test results at the time of progression.

Interim follow-up (Aug 2025):

- **7/10** dogs currently in CR; **1** dog has positive Cancer Dx test results.
- **2/10** dogs currently progressed/relapsed; **both** dogs have positive Cancer Dx test results.

Discussion

- IDEXX Cancer Dx testing detected 10/12 lymphoma cases (sensitivity ~83%), closely aligning with reported performance and reinforcing its diagnostic reliability.
- In these 10 dogs, Cancer Dx test positivity corresponded with clinical evidence of lymphoma at the initial visit, and negativity was generally observed with clinical remission during treatment, demonstrating concordance with clinical status.
- These results highlight the potential of Cancer Dx testing to monitor treatment response.

Future Directions

Validation in larger cohorts is warranted to confirm these findings.

References

- Additional references available upon request.

Acknowledgements

We thank the IDEXX Discovery and Development Teams and Pet Cancer Care Consulting for their support, the pet owners for their consent, and the dogs whose participation made this lymphoma study possible.



*PARR= PCR for Antigen Receptor Rearrangement